Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2

OBJECTIVE: In the PALOMA-2 trial, palbociclib in combination with letrozole prolonged progression-free survival (PFS) and exhibited an acceptable safety profile in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ABC). This post hoc a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelmon, Karen, Walshe, Janice M., Mahtani, Reshma, Joy, Anil A., Karuturi, Meghan, Neven, Patrick, Lu, Dongrui Ray, Kim, Sindy, Schnell, Patrick, Bananis, Eustratios, Schwartzberg, Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361185/
https://www.ncbi.nlm.nih.gov/pubmed/34388698
http://dx.doi.org/10.1016/j.breast.2021.07.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361185/
https://www.ncbi.nlm.nih.gov/pubmed/34388698
http://dx.doi.org/10.1016/j.breast.2021.07.017

Ejemplares similares